Chitosan modified Polymeric Nanoparticles for Nose to Brain Drug Delivery: An *In-vitro* & *In-vivo* Evaluation

Surbhi Sharma[1], Pammi Gauba[1], Amit Tyagi[2], Shweta Dang*[,1]

[1]*Department of Biotechnology, Jaypee Institute of Information Technology, Noida, UP, INDIA*

[2] *Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation, Delhi, INDIA*

* shweta.dang@jiit.ac.in

Table S1: Optimization of Chitosan coated Paroxetine loaded PLGA Nanoparticles on the basis of Entrapment Efficiency percentage developed with different concentrations of chitosan.

Figure S1: Results of particle size and zeta potential of PAR-PLGA-NPs (a) Particle size (b) Zeta Potential by Dynamic Light Scattering.

Figure S2: Results of particle size and zeta potential of PAR-CS-PLGA-NPs (a) Particle size (b) Zeta Potential by Dynamic Light Scattering.

Table S1: Optimization of Chitosan coated Paroxetine loaded PLGA Nanoparticles on the basis of Entrapment Efficiency percentage developed with different concentrations of chitosan.

Drug: Polymer Ratio	**Poloxamer (w/v)**	**Chitosan** (w/v)	**Entrapment Efficiency (%)**	**Drug Loading (%)**
1:10	1%	0.25%	77.78±2.87	8.89±1.4
		0.5%	87.5±1.87	13.4±1.3
		1%	Precipitation	



(a) **(b)**

Fig S1: Results of particle size and zeta potential of PAR-PLGA-NPs (a) Particle size (b) Zeta Potential by Dynamic Light Scattering.



(a) **(b)**

Fig S2: Results of particle size and zeta potential of PAR-CS-PLGA-NPs (a) Particle size (b) Zeta Potential by Dynamic Light Scattering.